+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ischemic Stroke Market and Forecast Analysis 2024

  • ID: 3797443
  • Drug Pipelines
  • January 2019
  • Region: Global
  • 163 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death. The majority of strokes occur due to blockages, and these are known as ischemic strokes. Strokes caused by bleeding are known as hemorrhagic strokes.

Market Snapshot
  • Market growth will slow as Plavix continues to lose market share as generic clopidogrel uptake increases.
  • Alteplase is prescribed to 65% of ischemic stroke patients in the US, Japan, and five major EU markets who receive thrombolytic therapy as an acute treatment.
  • Overall disease burden is expected to greatly increase, with ischemic stroke more common than hemorrhagic stroke.
  • Activase will continue to experience strong uptake while Aggrenox and Plavix face declining sales.
  • The large-scale Xarelto study was recently suspended, and there are no other pipeline drugs in Phase III trials.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: ISCHEMIC STROKE (Published on 02 July 2018)
Overview
Market Overview And Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Aspirin
Product Profile: Plavix

TREATMENT: ISCHEMIC STROKE (Published on 14 December 2016)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Current Treatment Options
Prescribing Trends

EPIDEMIOLOGY: STROKE (Published on 07 January 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: ISCHEMIC STROKE (Published on 02 July 2018)
Overview
Executive Summary
Product Overview
Product Profile: Activase
Product Profile: Aggrenox
Product Profile: Aspirin
Product Profile: Plavix

PIPELINE: ISCHEMIC STROKE (Published on 02 July 2018)
Overview
Executive Summary
Clinical Pipeline Overview
Recently Discontinued Drugs
Additional Pharma Intelligence Pipeline Resources

LIST OF FIGURES
Figure 1: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 3: Patient-based forecast methodology for ischemic stroke
Figure 4: Price sources and calculations, by country
Figure 5: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 6: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 7: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 8: Plavix for ischemic stroke – SWOT analysis
Figure 9: The authors drug assessment summary of Plavix for ischemic stroke
Figure 10: The authors drug assessment summary of Plavix for ischemic stroke
Figure 11: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Mean percentage of patients presenting with stroke-like symptoms diagnosed with particular indications, by country, 2015
Figure 13: Mean percentage of ischemic stroke patients receiving each treatment regimen in the US, Japan, and five major EU markets, by country, 2015
Figure 14: Mean percentage of ischemic stroke patients receiving each thrombolytic therapy in the US, Japan, and five majorEU markets, by country, 2015
Figure 15: Mean percentage of ischemic stroke patients receiving each neuroprotective therapy in the US, Japan, and five major EU markets, by country, 2015
Figure 16: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the acute treatment setting, by country, 2015
Figure 17: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the secondary prevention setting at first-line, by country, 2015
Figure 18: Mean percentage of ischemic stroke patients who progress to second-line treatment in the secondary prevention setting, by country, 2015
Figure 19: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in secondary prevention setting at second-line, by country, 2015
Figure 20: Trends in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 21: Trends in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 22: Trend in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 23: Trends in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Figure 24: Activase for ischemic stroke – SWOT analysis
Figure 25: The authors drug assessment summary of Activase for ischemic stroke
Figure 26: The authors drug assessment summary of Activase for ischemic stroke
Figure 27: Aggrenox for ischemic stroke – SWOT analysis
Figure 28: The authors drug assessment summary of Aggrenox for ischemic stroke
Figure 29: The authors drug assessment summary of Aggrenox for ischemic stroke
Figure 30: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 31: The authors drug assessment summary of Aspirin for ischemic stroke
Figure 32: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 33: Plavix for ischemic stroke – SWOT analysis
Figure 34: The authors drug assessment summary of Plavix for ischemic stroke
Figure 35: The authors drug assessment summary of Plavix for ischemic stroke
Figure 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Distribution of total market sales across ischemic stroke subgroups, 2016–25
Table 2: Summary of drug classes and molecules included in The authors ischemic stroke patient-based forecast
Table 3: Patent expiries occurring within the ischemic stroke market during the forecast period, 2016–25
Table 4: Exchange rates used for calculating prices
Table 5: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
Table 6: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 7: Plavix drug profile
Table 8: Plavix pivotal trial data in ischemic stroke
Table 9: Plavix ongoing late-phase clinical trials in ischemic stroke
Table 10: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
Table 12: Overview of risk factors for a first transient ischemic attack or ischemic stroke
Table 13: Mean percentage of ischemic stroke patients that have co-morbidities in the US, Japan, and five major EU markets, by country, 2015
Table 14: Common transient ischemic attack and ischemic stroke symptoms
Table 15: Overview of tests used in ischemic stroke and transient ischemic attack patients, by major category
Table 16: Treatments available for ischemic stroke across the US, Japan, and five major EU markets
Table 17: Mean percentage of ischemic stroke patients receiving each type of therapy in the US, Japan, and five major EU markets, by country, 2015
Table 18: Overview of inclusion and exclusion criteria for patients eligible for alteplase treatment in the US
Table 19: Mean percentage of ischemic stroke patients that progress to secondary prevention in the US, Japan, and five major EU markets, by country, 2015
Table 20: Sources used for the epidemiological analysis of stroke incidence in the US, Japan, and five major EU markets, by country
Table 21: Sources used for the epidemiological analysis of stroke prevalence in the US, Japan, and five major EU markets, by country
Table 22: Diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 23: Diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 24: Diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 25: Diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018–38
Table 26: Key marketed drugs for ischemic stroke
Table 27: Activase drug profile
Table 28: Activase pivotal trial data in ischemic stroke
Table 29: Aggrenox drug profile
Table 30: Aggrenox pivotal trial data in ischemic stroke
Table 31: Aggrenox late-phase trial data in ischemic stroke
Table 32: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 33: Plavix drug profile
Table 34: Plavix pivotal trial data in ischemic stroke
Table 35: Plavix ongoing late-phase clinical trials in ischemic stroke
Table 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 37: Late-stage compounds that were recently discontinued for ischemic stroke
Table 38: Ampyra drug profile
Table 39: Ampyra late-phase trial data in ischemic stroke
Table 40: Brilinta drug profile
Table 41: Brilinta late-phase trial data in ischemic stroke
Table 42: Desmoteplase drug profile
Table 43: Desmoteplase late-phase trial data in ischemic stroke
Table 44: Xarelto drug profile
Table 45: Xarelto late-phase trial data in ischemic stroke
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll